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Abstract Hereditary Spastic Paraplegia (HSP) is a
clinically and genetically heterogeneous group of neuro-
logical disorders that are characterized by progressive
spasticity of the lower extremities. We describe an
extended consanguineous Saudi family in which HSP is
linked to SPG18, a previously reported autosomal
recessive locus, and show that it is associated with a
nullimorphic deletion of ERLIN2, a component of
endoplasmic reticulum associated degradation. This find-
ing adds to the growing diversity of cellular functions that
are now known to be involved in the maintenance of the
corticospinal tract neurons.
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Brief report
Hereditary Spastic Paraplegia (HSP) is a clinically and
genetically heterogeneous group of neurological disorders
that are characterized by progressive spasticity that typical-
ly affects the lower extremities but can extend cranially as
the disease advances [1]. When manifestations other than
motor dysfunction are present, the designation complicated
or complex (as opposed to “pure”) HSP is often used [2].
Autosomal recessive and dominant as well as X-linked
forms have been described clinically and later corroborated
by the delineation of the underlying loci (designated SPG),
many of which have been solved at the gene level [3].
Interestingly, the genes identified to date serve myriad
functions including membrane trafficking, myelination,
neurotrophy, cytoskeleton organization, chaperone activity
and mitochondrial functions [3]. Identifying new HSP
genes will likely, therefore, shed light on other aspects of
the cellular process required for the maintenance of motor
neurons.
We have identified an extended consanguineous Saudi
family with five affected members with HSP (Fig. 1a).
The two siblings (1 and 2) were referred to us for
evaluation because of progressively worsening spasticity
and intellectual disability. Patient 1 is an 8 year old boy
whose pregnancy and neonatal history was unremarkable.
He sat at 1 year and walked holding onto furniture at
24 months. At 30 months parents noticed progressive
tightening of his lower extremities which progressed to
the upper extremities at 4 years of age at which point he
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DOI 10.1007/s10048-011-0291-8was completely wheel chair-bound. His expressive
language never progressed beyond mama and dada but
he regressed to babbling. Seizures were first noted at
7 years and EEG was severely abnormal with generalized
slowing of background, and presence of generalized slow
spike and wave activities compatible with the diagnosis
of atypical absence epilepsy. MRI/MRS brain was normal
as was a metabolic screen, blood indices, CPK level,
thyroid function test and EM of lymphocytes. Patient 2 is
the 3 year old sister of Patient 1. Her delivery was via
C/S because of breech presentation and she was
diagnosed with congenital hip dislocation on newborn
exam. Her subsequent course was remarkably similar to
her brother’s except that she did not have seizures. A
similar panel of investigations revealed normal results
although EEG was not performed. Unfortunately, the
three maternal uncles could not come for evaluation but
reports available indicate severe intellectual disability,
aphasia and marked hypertonia but no seizures.
Given the consanguinity loop that connects all
affected members of this family, we hypothesized that
a common autozygous interval will be shared by the
affected members consistent with autosomal recessive
inheritance caused by a homoallelic mutation [4].
Indeed, autozygosity mapping revealed only a single
locus shared across all the patients we analyzed, an
18.2 Mb interval on 8p12–8q11.22. This was further
c o n f i r m e db yl i n k a g ea n a l y s i sw h i c hr e v e a l e dag e n o m e -
wide maximal LOD score of 4.205 to this interval
(Fig. 1b). No other peak crossed the 3.0 linkage
threshold. We assessed all peaks of >2.5 LOD score for
overlap with any SPG locus, whether autosomal dominant
or recessive. The only overlap we noted was with our
maximal linkage peak, which overlapped with the
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Fig. 1 a Pedigree of the family described in this study. Clinical details
for patients V:1 and V:2 are provided in the text. Individuals with red
asterisks underneath were utilized for linkage analysis. b Genome-
wide linkage analysis using the Affymetrix Axiom microarray
platform and EasyLinkage v5.08 software revealed a single maximal
peak on chromosome 8 with a LOD score of 4.2. Inset: chromosome-
specific display showing close-up of linkage region on chromosome 8.
c Overlap of the linkage interval in this study (in red) with the one
previously published by Al-Yahyaee et al. [5] (in blue) refined the
critical interval to a region flanked by the FUT10 and ZMAT4 genes.
Physical position of markers is based on the 2006 assembly (hg18).
The dashed curly bracket indicates the 20 kb deleted region, along
with the approximate breakpoint positions and the genes affected. d
Electrophoresis gel image showing results of RT-PCR conducted on
two patients (V:1, V:2 from A), two obligate carriers (IV:9, IV:10), one
normal control and one negative control containing no template. The
GAPDH data confirms presence of cDNA in patient samples
334 Neurogenetics (2011) 12:333–336previously reported SPG18 locus [5]. The remarkable
similarity in phenotype with the two Omani families who
defined that locus led us to hypothesize that a similar
locus underlies the disease in our family, which allowed
us to further narrow the interval to 7.6 Mb flanked by the
heterozygous SNP rs10954899 at the proximal end and
D8S532 at the distal end (Fig. 1c). This reduced the
number of genes in the candidate interval from 118 to 57
genes. Of these, UNC5D, RAB11FIP1 and ERLIN2 were
selected for capillary sequencing based on cell biology
function and mouse phenotype if known. No pathogenic
mutations were identified in the first two genes. However,
the two alternative initiation exons of ERLIN2 consis-
tently failed to amplify in patients compared to controls
and unaffected siblings, whereas the remaining exons
amplified normally (primer sequences are provided in
Table 1). This pattern indicated the possibility of a large-
scale genomic deletion and segregated with the disease
state in all five patients and in individuals IV:9–IV:16 (Fig. 1a).
To delineate the deletion breakpoints we designed
primers specific for the genomic DNA upstream of
ERLIN2, at 1 kb intervals. Amplification of patient DNA
alongside normal controls revealed an approximately
20 kb deletion, with the distal breakpoint near physical
position 37,694,857 (Build NCBI36) and the proximal
breakpoint near 37,714,575 immediately upstream of
ERLIN2 exon 2 (Fig. 1c).This deletion is not described
in the Toronto database of genomic variants (http://projects.
tcag.ca/variation). Further experiments indicated that exon 2,
while not deleted, had been genomically repositioned (data
not shown). This 20 kb interval spans two protein-coding
genes, ERLIN2 and FLJ34378 (RP11-863 K10.7). The latter
gene is of unknown function and is totally deleted in our
patients. To assay the effects of this genomic deletion on
ERLIN2 transcription we performed reverse-transcriptase
PCR (RT-PCR) on lymphoblast RNA. Intriguingly there
was no transcription evident in the patient samples,
unlike obligate carriers and normal controls who dis-
played robust RT-PCR products (Fig. 1d).Our data
indicate that the loss of the ERLIN2 initiation exons along
with mislocalization of exon 2 is sufficient to cause a
nullimorphic allele.
While there is also loss of genomic DNA (and thus
transcription) from the neighboring FLJ34378 gene, a
recent article by Yildirim et al. describes a familial case of
motor dysfunction and intellectual disability that was
linked to a 2 base pair frameshift insertion in ERLIN2.
Although not classified as spastic paraplegia, their patient
phenotype displays certain similarities with ours [6]. In
addition, a survey of the 1,000 Genomes Project (http://
browser.1000genomes.org) does not reveal any truncating
variants within the protein-coding sequences of ERLIN2,
while FLJ34378 includes rs112819064, a deletion variant
within the putative coding region that is predicted to cause
premature truncation. Hence, while we cannot exclude the
possibility of FLJ34378 contributing a modifier effect to
our family, a review of the literature strongly implicates
ERLIN2 depletion as the likely cause of our patients’
phenotype. We have therefore identified a novel ERLIN2
mutation that defines the SPG18 locus.
ERLIN2 (also known as SPFH2) is an SPFH domain-
containing protein. The domain, named based on simi-
larities to the proteins stomatin, prohibitin, flotillin, and
HflC/K, defines a family of around 100 mammalian
proteins that have in common the ability to assemble into
large oligomeric structures and localize to cholesterol-
rich, detergent-resistant membranes [7]. This protein has
been identified as a mediator of the endoplasmic reticulum
degradation (ERAD) pathway, a multistep process that
involves the proper ubiquitin–proteasome mediated deg-
radation of proteins [8]. ERAD does not only target
Table 1 Sequences of primers used for genomic DNA and cDNA
amplification in this study
Primer name Sequence
ERLIN2_Ex1_F 5′ CCAGCTACGGCCATTGAC 3′
ERLIN2_Ex1_R 5′ GAAAGTGACGGGTCAGCC 3′
ERLIN2_Ex1b_F 5′ AGGAAGTCGCGTGCTGAG 3′
ERLIN2_Ex1b_R 5′ GGTGACTGACTGCAAAGTTCA 3′
ERLIN2_Ex2_F 5′ GAGGTCCTCTCGCTGTTGTG 3′
ERLIN2_Ex2_R 5′ AGGAAAGCAATGACCAGGAA 3′
ERLIN2_Ex3_F 5′ GAAGGGAAAGTTGACCCTCA 3′
ERLIN2_Ex3_R 5′ TCTCTGGCTTTATCTTGAAGGA 3′
ERLIN2_Ex4_F 5′ CCAGGACAAAGGCATTTAGG 3′
ERLIN2_Ex4_R 5′ TCACTGTCTCTTCCTGCAACC 3′
ERLIN2_Ex5+6_F 5′ ACATCTTACGCCATCACCCT 3′
ERLIN2_Ex5+6_R 5′ TTCTAGAATGGACCTTGTCTTCA 3′
ERLIN2_Ex6b_F 5′ TCTGTTTAAACTCACTGCCAGAA 3′
ERLIN2_Ex6b_R 5′ CCTCTTCAGGGACATTAGGG 3′
ERLIN2_Ex7+8_F 5′ GCACTTTACCTCATCCTGCC 3′
ERLIN2_Ex7+8_R 5′ GCAGCTTTGGTTACCTCTGG 3′
ERLIN2_Ex9_F 5′ GGAGTTTGCCTCTCTTCAGC 3′
ERLIN2_Ex9_R 5′ CTCCTTGCATCTTCCCACC 3′
ERLIN2_Ex10_F 5′ ACACTCAGCTCGGGTGAAAG 3′
ERLIN2_Ex10_R 5′ CAGTTAAAGGGCAAAGGCAA 3′
ERLIN2_Ex11_F 5′ TTCCCATAGCCTCTGCACTT 3′
ERLIN2_Ex11_R 5′ CAACACTGGAAACTCTCCTGC 3′
ERLIN2_Ex12_F 5′ TGCTCCAAGATCTGAGATGACT 3′
ERLIN2_Ex12_R 5′ CAAAGGTCAAGCCCATGATT 3′
ERLIN2_RT-PCR_F 5′ TGCTCCCTTTCATCACATCA 3′
ERLIN2_RT-PCR_R 5′ CCAGGAAGTTCACCACTTCAA 3′
GAPDH_RT-PCR_F 5′ GGTGAAGGTCGGAGTCAAC 3′
GAPDH_RT-PCR_R 5′ ATGGGTGGAATCATATTGGA 3′
Neurogenetics (2011) 12:333–336 335aberrant proteins but also certain normal proteins that are
needed to be maintained in a tightly regulated level of
activity to maintain cellular homeostasis [9]. Inositol 1,4,5-
trisphosphate(IP3) receptors (IP3Rs) are a good example of
the latter since ERAD of IP3Rs is coupled with their
activation by IP3 so the resulting channel opening is kept
transient [10]. ERLIN2 was found, among other factors, to
mediate ERAD of IP3R. Specifically, ERLIN2 was found to
form a heterodimer with SPFH1 and deficiency of this
complex induced by RNAi led to failure of ERAD of IP3R.
In fact ERLIN2 deficiency, while still permitting the
formation of stable SPFH1 homodimers, led to failure of
SPFH1 to effect activation of IP3R ERAD [11]. Our
mutation, in the event it permits transcription, leads to loss
of a domain that is essential for the formation of the
heterodimer with SPFH1 [11].
An attractive model, therefore, arises for the patho-
genesis of HSP in our patients. Deficiency of ERLIN2
leads to impaired ERAD of IP3R which leads to
persistent activation of IP3 signaling and channel
opening thus keeping neurons in a state of hyperactivity.
This is consistent with the recently demonstrated role of
IP3R in the neuronalcalcium signaling repertoire [12].
However, we caution that experimental evidence is needed
to support this model and that ERLIN2 may exert its
pathogenesis through the impaired degradation of other
proteins.
In summary, we have defined the locus for SPG18 using
a Saudi family that bears a null mutation in ERLIN2. The
biology behind ERLIN2 function opens intriguing possi-
bilities as to the mechanism underlying HSP in our patients
and others who link to this gene.
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